Latest studies
- Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseLithuania - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseLithuania - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseLithuania - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseLithuania - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseLithuania - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaLithuania - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisLithuania - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with very high levels of a type of fat in their blood called triglycerides. We want to see if it helps lower these levels and prevent related health problems.
Severe hypertryglyceridemiaLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures
This study is testing a new medicine, EQU-001, for people with epilepsy whose seizures aren't fully controlled by their current treatment. It aims to see if the new medicine can reduce the number of seizures compared to a dummy medicine.
EpilepsyLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma
This study looks at a new inhaler, CHF6001, for people with asthma that isn't fully controlled. Researchers want to see if adding this new inhaler to their usual medication helps reduce asthma attacks over 52 weeks and is safe.
AsthmaLithuania - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Metastatic Colorectal CancerLithuania - Active not recruiting
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This study looks at how well a medicine called Humira works and how safe it is for children aged 6 to 17 with Crohn's disease. It also compares Humira to other common treatments like azathioprine, 6-mercaptopurine, or methotrexate, watching patients over a long time.
Crohn's DiseaseLithuania - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisLithuania - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsLithuania - Active not recruitingPHASE3
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
This study looks at the long-term safety and effectiveness of a new medicine, ianalumab, for people with Sjögren's Syndrome. It's for those who have already completed an earlier study and aims to see how well the treatment works and if it has any long-term side effects.
Sjogrens SyndromeLithuania - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesLithuania - Active not recruitingNA
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
This study looks at a new way to treat hardened arteries in the heart. It uses special sound waves to gently break up calcium buildup, making it easier for doctors to open the artery and improve blood flow. The aim is to see how well this treatment works.
Coronary Artery DiseaseCoronary Artery CalcificationLithuania - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
Systemic Lupus ErythematosusLithuania - Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Gaucher disease over time, whether or not they are receiving treatment. There's also a sub-study for pregnant women with Gaucher disease to see how their pregnancies and babies' health progress. It helps doctors learn more about the condition.
Gaucher DiseaseCerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency DiseaseGlucosylceramide Beta-Glucosidase Deficiency DiseaseLithuania - Active not recruitingPHASE3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
This study tested new treatments for Chronic Lymphocytic Leukemia (CLL), a type of blood cancer, in people who had not been treated before. It compared different drug combinations to see which worked best to slow down or stop the cancer's progress.
Chronic Lymphocytic LeukemiaLithuania - RecruitingPHASE1, PHASE2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
This study is looking at a new medicine called revumenib for different types of leukaemia that have come back or not responded to treatment. It aims to find the right dose and see how well it works and if it's safe for people with certain genetic changes in their leukaemia.
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMixed Lineage Acute LeukemiaMixed Phenotype Acute LeukemiaLithuania - Recruiting
Trifecta-Kidney cfDNA-MMDx Study
This study looks at new ways to check for rejection in kidney transplant patients. It compares a new blood test (DD-cfDNA) with a special biopsy test (MMDx) and traditional checks to see which is best at finding rejection accurately.
Kidney Transplant RejectionLithuania - RecruitingNA
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
This study looks into a new, faster way to give radiation treatment for early-stage breast cancer. Instead of many sessions, it uses a single, high-dose treatment to see if it's just as good at treating the cancer and has good cosmetic results.
Breast NeoplasmsLithuania - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
This study looks at a medicine called Panzyga to see if it can prevent serious infections in people with certain autoimmune conditions. Participants receive either Panzyga or a salt solution to see if the medicine helps keep them healthier.
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.Lithuania - RecruitingPHASE2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
This study looks at new medications for adults with moderate to severe Crohn's disease. Researchers want to see how well these 'targeted therapies' work and if they cause side effects, to find better ways to manage the condition.
Crohn's DiseaseLithuania - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This study looks at the everyday safety and how well a drug called tolebrutinib is tolerated over a long time. It's for adults with different types of multiple sclerosis (MS) who have already been in earlier tolebrutinib studies.
Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple SclerosisLithuania - Not yet recruitingNA
Training in HFpEF-PH
This study looks at a special exercise program for people with heart failure (HFpEF) and high blood pressure in their lungs (pulmonary hypertension). We want to see if it's safe, helps them exercise more easily, and improves their overall health and heart function.
Pulmonary Hypertension Due to Left Heart DiseaseHeart Failure With Preserved Ejection FractionLithuania - Active not recruitingPHASE3
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
This study is testing a new injection treatment for house dust mite allergy. It aims to see if it reduces allergy symptoms and is safe for adults with moderate to severe allergic rhinitis, with or without asthma. The treatment is given over one year.
House Dust Mite AllergyHouse Dust Mite RhinitisLithuania - Active not recruitingPHASE3
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
This study is testing a new medicine, barzolvolimab, for people with chronic spontaneous urticaria (CSU), also known as chronic hives. It aims to see if the medicine is safe and helps reduce hives better than a dummy medicine (placebo) for those whose current treatments aren't enough.
Chronic Spontaneous UrticariaLithuania - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseLithuania - Recruiting
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
This study aims to find new, easy, and affordable ways to test for bowel cancer, especially for people at higher risk. The goal is to detect cancer earlier using new screening methods that are simple to use.
Colorectal CancerLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.
This study is testing a new combination of treatments for advanced lung cancer. It combines a new drug, eftilagimod alfa, with existing treatments like pembrolizumab and chemotherapy, to see if it can help people live longer and improve their quality of life. Participants will be randomly assigned to different treatment groups.
Advanced/metastatic non-small cell lung cancer (NSCLC)Lithuania - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study looks at the long-term safety and effectiveness of a medicine called Upadacitinib for people with ulcerative colitis. It's for those who haven't fully responded to previous treatment or have completed an earlier study.
Ulcerative Colitis (UC)Lithuania - Active not recruitingPHASE3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
This study is for men with cancer who are already taking darolutamide in another Bayer study and are doing well. It lets them keep taking the same medicine at the same dose, continuing their treatment journey under medical supervision.
CancerLithuania - Active not recruitingPHASE3
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
This study is looking at a new medicine called nemolizumab for people with moderate to severe eczema. It aims to understand how safe and effective the medicine is over a long period. Participants would have been in a previous nemolizumab study.
Moderate-to-Severe Atopic DermatitisLithuania - RecruitingPHASE2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It aims to see if the medicine is safe and helps improve symptoms compared to a dummy pill. It's a pill taken by mouth.
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active SevereLithuania - RecruitingPHASE3
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
This study looks at new ways to treat acute myeloid leukaemia (AML) that has come back or hasn't responded to earlier treatment. It compares stronger treatments with gentler ones to see which works best for patients in their first or second relapse.
Acute Myeloid LeukemiaRelapse/RecurrenceLithuania - RecruitingPHASE3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
This study is for children aged 6 months to 17 years with long-term kidney disease (CKD) and too much protein in their urine. It tests a new medicine called finerenone to see if it can improve kidney health alongside existing treatments. Researchers want to check how safe and effective it is.
Chronic Kidney DiseaseProteinuriaLithuania - Active not recruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaLithuania - Enrolling by invitation
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
This study looks at how well Esperoct® works and if it has side effects for men and boys with haemophilia A. Participants will receive their usual treatment and share information about their health over several years.
Haemophilia ALithuania - RecruitingPHASE3
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
This study looks at a new drug called blinatumomab for babies under one year old with a specific type of leukaemia (blood cancer). The aim is to make treatments better for these tiny patients by adding blinatumomab to their usual care. It's a key step in finding more effective ways to fight this illness.
Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaLithuania - Active not recruitingPHASE3
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
This study is testing a new medicine, povetacicept, for adults with a kidney condition called IgA Nephropathy. We want to see if it can help reduce protein in the urine and protect kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyLithuania - Active not recruitingPHASE3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This study is testing a new combination of medicines with chemotherapy for some upper gut cancers that have spread and can't be removed by surgery. It aims to see if the new combination works better than current treatments.
Advanced Upper Gastrointestinal Tract AdenocarcinomaLithuania - RecruitingPHASE3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This study is looking into the long-term safety and effectiveness of an inhaled medicine called seralutinib for adults with pulmonary arterial hypertension (PAH). Participants have already tried seralutinib in an earlier study and will continue to take it.
Pulmonary Arterial HypertensionLithuania - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
This study looks at a new combination treatment for advanced lung cancer. It compares giving a well-known drug (pembrolizumab) with or without an additional drug (sacituzumab govitecan) to see which is better at slowing the cancer's growth and helping people live longer.
Carcinoma, Non-Small-Cell LungLithuania - Active not recruitingPHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study looked at new ways to treat a type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). It compared a combination of medicines with standard chemotherapy to see if it could help people live longer. The study was changed partway through, so the focus shifted.
Small Cell Lung CarcinomaLithuania - Active not recruitingPHASE3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
This study is looking at a new medicine called sonelokimab for people with psoriatic arthritis who haven't tried powerful biologic drugs before. It wants to see if sonelokimab is safe and helps improve their arthritis and skin.
Arthritis, PsoriaticLithuania - Recruiting
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
This study, called SPECTA, collects information and samples from cancer patients to help scientists better understand cancer. It aims to improve how we diagnose and treat different types of cancer in the future by looking at many different aspects of the disease.
All Tumor TypesLithuania - RecruitingPHASE3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
This study is testing a new injection called Plozasiran for adults with very high triglyceride levels. Participants have already been in related studies and will receive the injection every three months for two years, while following a low-fat diet.
HypertriglyceridemiaLithuania